Worth revisiting the #BRCAway trial from #GU24 in the context of #GU25 and #Talapro2

With regard to evaluation of sequencing #Parp and #ARPI the numbers of pts are very small (8 with cross over) and the CIs are very wide.
#ProstateCancer